Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Abstract Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat relapsed or refractory hematological malignancies. However, the adverse effects of CAR-T cell therapies are complex and can be challenging to diagnose and treat. In this review, we summarize the major advers...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2023-10-01
|
| Schriftenreihe: | Journal of Biomedical Science |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s12929-023-00982-8 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|